Ajanta Pharma Publishes Q3 FY26 Financial Results in Newspapers
Ajanta Pharma published its unaudited Q3 FY26 results. For the quarter ended Dec 31, 2025, total income was ₹1,472.67 lakh and profit after tax was ₹18.79 lakh. For the nine months ended Dec 31, 2025, total income was ₹6,391.76 lakh and profit after tax was ₹45.95 lakh. EPS for the quarter was ₹0.21.
This is a standard disclosure of financial results as per SEBI regulations and does not contain any new strategic information or significant financial performance changes that would impact the company's valuation.
The announcement is a routine regulatory filing about the publication of financial results, with no significant positive or negative news.
Ajanta Pharma Limited has complied with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by publishing its un-audited financial results for the quarter and nine months ended December 31, 2025. The results were published on January 31, 2026, in the Mumbai editions of the Business Standard and Navakal newspapers.
The unaudited standalone financial results for the quarter ended December 31, 2025, show total income from operations at ₹1,472.67 lakh, with a profit after tax of ₹18.79 lakh. For the nine months ended December 31, 2025, the total income from operations was ₹6,391.76 lakh, and the profit after tax was ₹45.95 lakh.
Basic Earnings Per Share (EPS) for the quarter stood at ₹0.21, and diluted EPS was also ₹0.21. For the nine-month period, basic and diluted EPS were ₹0.50.
What to do with a filing like this
Ajanta Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ajanta Pharma Limited. Read the original for the full detail.